Roche is investing $750 million to double the size of its existing production facility at the Genentech campus in Hillsboro, Oregon, on the western outskirts of Portland.
The Swiss pharmaceutical giant’s latest outlay will fund construction of a fill-finish plant producing drug delivery devices, including prefilled syringes and auto-injectors that allow patients to self-administer treatments at home.
The 75-acre Hillsboro site has been producing oncology, immunology and neurology treatments for two decades since it first became operational.
Roche said the new facility will provide end-to-end filling of both low- and high-volume drug devices, giving the company flexibility to adapt as its portfolio continues to evolve.
The company expects the new plant to become operational in 2031 and create 250 new, high-wage manufacturing jobs at the site.
Ashley Magargee, CEO of Roche’s U.S. subsidiary Genentech, said: “Thanks to its skilled workforce and strong community, Hillsboro remains vital to our U.S. operations.”
Magargee added: “By adding end-to-end filling capabilities, this expansion deepens our commitment to manufacturing in the U.S. and gives us the flexibility to support a growing pipeline.”
The Hillsboro site has previously attracted significant capital, with Roche committing $125 million to an expansion there in 2015, a move that was projected to add up to 100 jobs at the facility.
That 2015 investment was itself part of a broader 2013 initiative worth $880 million aimed at bolstering Roche’s biologic drug manufacturing, which ultimately added 500 jobs across the U.S., Germany and Switzerland.
The Oregon expansion follows Roche’s decision earlier this year to scale up its Holly Springs, North Carolina facility from a planned $700 million investment to a total commitment of $2 billion, targeting fill-finish production for obesity and other metabolic condition treatments.
Both the Holly Springs and Hillsboro projects sit within a sweeping $50 billion U.S. investment pledge that Roche announced last April, positioning it alongside other major drugmakers seeking to sidestep potential Trump administration pharmaceutical tariffs through domestic manufacturing commitments.
Roche and Genentech together operate 13 manufacturing sites and 15 research and development facilities across the U.S., employing approximately 25,000 people across 24 locations in eight states.